This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
This is the fourth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,319.70.
GIS CAT O.PRF WBA ENB OPRF JCI HSY ABBV MMM POL MO IRET.PR DUKH GD IRET.PRC TRV IRET.PRB MAIN CMI ENB RY BNS JNJ TROW VZ WPC ABBV MSFT ADM PFE PM PFBC SCL IRET CTL OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM IRET.PRCL RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL CBL
Iron Mountain (NYSE:IRM) has about as strong a moat as you can get in any market sector, with its overall customer base of over 225,000 globally, and the high costs of changing physical storage companies. In its primary business of physical storage, it has no meaningful peers.
When investors think of dividend stocks, tech names don’t usually come to mind. Technology is a growth industry, and investors generally prefer that any idle, excess cash gets put back into the business. That’s the best ROI opportunity.
AVX IRM AAPL CSCO STX INFY MSFT NOK NYTAB QCOM
The market was definitely on the defensive last week, but when all was said and done, was still standing as of Friday’s closing bell. Even General Electric (NYSE:GE), which has been struggling ever since it was announced it was to be replaced by Walgreens (NASDAQ:WBA) as a Dow Jones component, managed to hammer out a gain, reversing a rough patch.
IRM GE CAT RAD WBA PPL NYTAB
This is the third month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $891.57.
GIS O.PRF WBA ENB OPRF JCI HSY ABBV MMM POL MO SMG IRET.PR DUKH GD IRET.PRC TRV IRET.PRB GPT.PRB MAIN BX CMI ENB RY BNS JNJ TROW GPT VZ ABBV MSFT WPC ADM PFE CLX PM PFBC SKT SCL CTL IRET OXLCM OXLCO TD ETN OXLCN BNS CM MSCA GPT.PRA INTC TD IBM IRET.PRCL RY TNTTF LYB O MSB DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL BMRC DLR CBL
This article is Update 29 (and the last) to my original article entitled "If I Had to Build An Income Portfolio Today".
GEO UNIT STAG.PRB STAG.PRC EPD TD SBRA STWD.WI VZA CALM WELL STAG TD HASI STAG.PRA SBRAP VTR DOC PEGI RY TNTTF VDE IRM RY ORI CLDT WES PEG VZ STWD OHI
The weather is heating up and it's time to put on the spectacles for the dividend stock watch list. I feel like I have been on the side lines for such a long time, not having purchased a stock in weeks. Over Memorial Day Weekend, I was able to take time aside and really focus on the quality of stocks that are out there. As others know, I came to find out that there are many opportunities out there for us and it is such a hard decision when it comes to which one to add to the dividend portfolio.
IRM GILD PEP JNJ PFE DAL
Like income? If you’re reading this, then you likely do. And odds are good you’re more than a little familiar with the usual suspects … utilities stocks like Southern Co (NYSE:SO), or diversified healthcare giant Pfizer Inc. (NYSE:PFE). The former is recession proof, while the latter always seems able to find a market by constantly reinventing its drug portfolio, making them a couple of the best income-producing assets the market has to offer.
SOJA SO PFZ NLSN OAK PFIZER HTGX HTGY IRM HTGZ HTGC 500680 PFE CVA OUT CWB
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to IRM / Iron Mountain Incorporated. (REIT) on message board site Silicon Investor.
as of ET